Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
A PHASE1/PHASE2 clinical study on Multiple Myeloma and Refractory Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2023 — Oct 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2019 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Houston, United States
- • Omaha, United States